Results 91 to 100 of about 12,603 (200)

Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy [PDF]

open access: yes, 2013
Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist in late-stage clinical development for the treatment of schizophrenia, as well as for bipolar disorder (manic/mixed and depressive episodes), and as an adjunctive agent for the ...
Leslie Citrome
core   +1 more source

c-Fos expression in the hypothalamic paraventricular nucleus after a single treatment with a typical haloperidol and nine atypical antipsychotics: a pilot study

open access: yesEndocrine Regulations, 2018
Objective. The aim of the present study was to find out whether acute effect of different doses of selected antipsychotics including aripiprazole (ARI), amisulpride (AMI), asenapine (ASE), haloperidol (HAL), clozapine (CLO), risperidone (RIS), quetiapine
Kiss Alexander
doaj   +1 more source

Medication and suicide risk in schizophrenia: A nested case-control study

open access: yes, 2013
Introduction: Patients with schizophrenia are at increased risk of suicide, but data from controlled studies of pharmacotherapy in relation to suicide risk is limited.
Bahmanyar, S.   +6 more
core   +1 more source

The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review [PDF]

open access: yes, 2017
Norepinephrine (NE) is recognized as having a key role in the pathophysiology of major depressive disorder (MDD) and schizophrenia, although its distinct actions via α-adrenergic receptors (α-ARs) are not well defined.
Anna Eramo   +4 more
core   +1 more source

The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder

open access: yesNeuropsychiatric Disease and Treatment, 2011
Charles L BowdenMood & Anxiety Disorder Division, Department of Psychiatry, UT Health Science Center, San Antonio, TX, USAObjectives: This article addresses the clinical role for ziprasidone used adjunctively with a mood stabilizer in maintenance
Charles L Bowden
doaj  

Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy

open access: yesDrug Design, Development and Therapy, 2020
Urooj A Khan,1 Uzma Parveen,2 Nazeer Hasan,1 Mohammad Zubair Ahmed,1 Suma Saad,1 Farhan J Ahmad,1 Gaurav K Jain1 1Nanoformulation Research Laboratory, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi ...
Khan UA   +6 more
doaj  

Commentary on strategies for switching antipsychotics [PDF]

open access: yes, 2008
Both the new generation of antipsychotics and the more traditional antipsychotic drugs produce an important and meaningful improvement in patients with schizophrenia, but most patients are neither cured nor free of symptoms.
John M Davis   +11 more
core   +1 more source

Atypical antipsychotics in the treatment of early-onset schizophrenia

open access: yesNeuropsychiatric Disease and Treatment, 2015
Michal Hrdlicka, Iva Dudova Department of Child Psychiatry, Charles University Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic Abstract: Atypical antipsychotics (AAPs) have been successfully used in early-onset ...
Hrdlicka M, Dudova I
doaj  

Ziprasidone Hydrocloride: What Role in the Management of Schizophrenia?

open access: yesJournal of Central Nervous System Disease, 2011
Background Since schizophrenia is considered one of the top ten causes of disease-related disability in the world, the development of second-generation (atypical) antipsychotics (SGAs) has increased the hopes of psychiatrists.
Chiara Mattei   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy